Clinical trials: Distress Due to COVID-19
COVID-19, ARDS, Human
Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19
Surfactant replacement therapy (SRT) improves oxygenation and survival in NRDS and some infant ARDS. SRT was tried in adult ARDS with conflicting results.
- Trial name
- Caards-1 (NCT04384731)
- Testing
- poractant alfa
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Dr Christophe LENCLUD
Covid-19, Acute Respiratory Failure
Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)
This study is a prospective, phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of mavrilimumab in hospitalized patients with acute respiratory failure requiring oxygen…
- Conditions
- Covid-19, Acute Respiratory Failure, ARDS, Human, Sars-CoV2
- Trial name
- COMBAT-19 (NCT04397497)
- Testing
- Mavrilimumab
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale San Raffaele
ARDS
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
Multicenter investigation featuring an open-label lead-in followed by a double blinded, randomized, placebo-controlled Phase 2/3 part to evaluate the safety and efficacy of MultiStem therapy in subjects with moderate to severe…
- Trial name
- MACoVIA (NCT04367077)
- Testing
- MultiStem
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Healios K.K.
Covid19
A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19
This is phase II study to evaluate the safety and efficacy of inhaled Ampion in adults with respiratory distress due to COVID-19
- Trial name
- NCT04868890
- Testing
- Ampion
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Ampio Pharmaceuticals. Inc.
Respiratory Infection Virus, Respiratory Failure
Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19
A randomized, double-Blind, placebo-controlled trial aimed to investigate the safety and efficacy of sivelestat on treating adult patients with COVID-19-related acute respiratory distress syndrome (ARDS)
- Trial name
- NCT05697016
- Testing
- Sivelestat Sodium for Injection
- Volunteers
- 238 people
- Sponsor
- Beijing Tiantan Hospital
Covid 19
Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19
Acute Respiratory Distress Syndrome (ARDS) is the main cause of death from COVID-19. One of the main mechanisms for ARDS is the violent storm of cytokines and chemokines, which cause uncontrolled fatal systemic inflammation by…
- Trial name
- COVID-19 (NCT04416139)
- Testing
- Infusion IV of Mesenchymal Stem cells
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
Sedation Complication, Acute Respiratory Distress Syndrome Due to COVID-19
Assessment of Sedation Depth Using Processed EEG in ICU Patients With ARDS Receiving Neuromuscular Blockade: A Prospective Observational Study"
"In intensive care units, therapeutic paralysis has been a routine treatment method for many years in a select group of patients.
- Conditions
- Sedation Complication, Acute Respiratory Distress Syndrome Due to COVID-19, Anesthesia Awareness
- Trial name
- NCT06337877
- Testing
- Depth of sedation monitoring
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Tepecik Training and Research Hospital
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).
- Trial name
- NCT04366830
- Testing
- Remestemcel-L
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
COVID, Corona Virus Infection
Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19
COVID-19 patients with a severely symptomatic progression with development of an Acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 need prolonged intensive care treatment involving pharmacological immobilization…
- Conditions
- COVID, Corona Virus Infection, Sars-CoV2
- Trial name
- NCT04397172
- Testing
- Study Arm
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Mechanical Ventilation Complication, Hypoxemia
Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure
To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe…
- Conditions
- Mechanical Ventilation Complication, Hypoxemia, Acute Respiratory Distress Syndrome Due to COVID-19, COVID-19 Respiratory Infection
- Trial name
- REDEEM (NCT05562505)
- Testing
- Venovenous ECMO
- Where
- 7 sites in Australia, Germany
- Volunteers
- 140 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy.
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral
- Trial name
- NCT05123755
- Testing
- AV-001 Injection
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vasomune Therapeutics, Inc.
ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19 Acute Respiratory Distress Syndrome
Pulmonary Inflammation in COVID-19 ARDS
Patients older than 18 years of age, with COVID-19 related ARDS (C-ARDS) hospitalized in the ICU and invasively mechanically ventilated will be included in the study. This is an observational cohort study.
- Trial name
- IMPU-COVID (NCT04935450)
- Testing
- Bronchoalveolar lavage
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Acute Respiratory Distress Syndrome
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare…
- Trial name
- NCT04390152
- Testing
- Wharton's jelly derived Mesenchymal stem cells.
- Where
- 2 sites in Colombia
- Volunteers
- 6 people
- Sponsor
- BioXcellerator
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
Sars-CoV2, ARDS
Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection
The purpose of this study is to evaluate if a postural recruitment maneuver (PRM) improves the aeration and distribution of lung ventilation in patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19…
- Trial name
- NCT04475068
- Testing
- Lateral Position (left and right lateral decubitus)
- Where
- Peru
- Volunteers
- 15 people
- Sponsor
- Hospital Nacional Edgardo Rebagliati Martins
Acute Respiratory Distress Syndrome, Severe Pneumonia
One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19
The latest epidemiological data published from Chine reports that up to 30% of hospital-admitted patients required admission to intensive care units (ICU).
- Conditions
- Acute Respiratory Distress Syndrome, Severe Pneumonia, Respiratory Failure
- Trial name
- NCT04457505
- Where
- 31 sites in Spain
- Volunteers
- 8,500 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
COVID-19
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
- Trial name
- SARPAC (NCT04326920)
- Testing
- Sargramostim, Control
- Where
- 4 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- University Hospital, Ghent
Psychological Distress, Quality of Life
Psychological Impairment Due to Covid-19
Hospital staff and emergency personnel are expected to suffer impaired psychological outcomes during a pandemic in terms of Quality of Life, anxiety, depression or other outcomes.
- Trial name
- NCT04368312
- Testing
- No intervention
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen